<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39335528</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Kawasaki Disease Diagnosis and Treatment in over 1000 Patients: A Continuum of Dysregulated Inflammatory Responses.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2014</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines12092014</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Kawasaki disease (KD) is a pediatric vasculitis, leading to coronary artery aneurysms (CAAs) in ~4-14%. Attention to the etiology and course of KD was generated by the close mimic of a SARS-CoV-2-induced phenotype, called multisystem inflammatory syndrome in children (MIS-C).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 1179 cases were collected from 2012 with ~50% of cases retrospectively included. Clinical characteristics were described and risk factors for CAA (persistence) were investigated. Phenotypic patterns of the prospectively included KD patients were evaluated. These patterns were also compared to the seronegative KD and seropositive MIS-C cases identified during the SARS-CoV-2 pandemic.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">KD mostly affected boys and children &lt; 5 years. IVIG resistance, CAAs, and giant CAAs occurred in 24.5%, 21.4%, and 6.6%, respectively. Giant CAAs were significantly more likely to normalize to a normal <i>Z</i> score in patients that were younger than 2.5 years old at the time of initial giant CAA (χ<sup>2</sup> test <i>p</i> = 0.02). In our prospective (SARS-CoV-2-seronegative) KD series, there was a diminishing male predominance over time, whereas the proportions of incomplete presentations (<i>p</i> &lt; 0.001) and patients with circulatory shock (<i>p</i> = 0.04) increased since the COVID-19 pandemic. Pre- and post-pandemic KD cases presented with different levels of C-reactive protein, thrombocyte counts, and hemoglobin levels over the years. Compared to pandemic KD, SARS-CoV-2-seropositive MIS-C patients were older (<i>p</i> &lt; 0.001), and more often required intensive care admission (<i>p</i> &lt; 0.001), with a gradual decrease over time between 2020 and 2022 (<i>p</i> = 0.04). KD carried a substantial risk of CAA development in contrast to MIS-C.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">the phenotypic changes seen over the last twelve years of our prospective follow-up study suggest a spectrum of hyperinflammatory states with potentially different triggering events within this clinical entity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Netea</LastName><ForeName>Stejara A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Pediatric Immunology, Rheumatology and Infectious Disease, Emma Children's Hospital, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Immunology, Amsterdam Institute for Infection &amp; Immunity, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biesbroek</LastName><ForeName>Giske</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pediatric Immunology, Rheumatology and Infectious Disease, Emma Children's Hospital, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Stijn</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pediatric Immunology, Rheumatology and Infectious Disease, Emma Children's Hospital, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagelkerke</LastName><ForeName>Sietse Q</ForeName><Initials>SQ</Initials><Identifier Source="ORCID">0000-0001-8359-4016</Identifier><AffiliationInfo><Affiliation>Pediatric Immunology, Rheumatology and Infectious Disease, Emma Children's Hospital, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Hematology, Sanquin Research Institute, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawasaki Study Group</LastName></Author><Author ValidYN="Y"><LastName>Cahal Group</LastName></Author><Author ValidYN="Y"><LastName>Kiri Group</LastName></Author><Author ValidYN="Y"><LastName>Kuipers</LastName><ForeName>Irene M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Pediatric Cardiology, Emma Children's Hospital, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuijpers</LastName><ForeName>Taco W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Pediatric Immunology, Rheumatology and Infectious Disease, Emma Children's Hospital, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Immunology, Amsterdam Institute for Infection &amp; Immunity, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Hematology, Sanquin Research Institute, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N/A</GrantID><Agency>Dutch foundation Fonds Kind &amp; Handicap</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>Anonymous donor</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">KD</Keyword><Keyword MajorTopicYN="N">Kawasaki disease</Keyword><Keyword MajorTopicYN="N">MIS-C</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">hyperinflammation</Keyword><Keyword MajorTopicYN="N">mucocutaneous lymph node syndrome</Keyword><Keyword MajorTopicYN="N">multisystem inflammatory syndrome in children</Keyword><Keyword MajorTopicYN="N">phenotypic patterns</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39335528</ArticleId><ArticleId IdType="pmc">PMC11428402</ArticleId><ArticleId IdType="doi">10.3390/biomedicines12092014</ArticleId><ArticleId IdType="pii">biomedicines12092014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kawasaki T., Kosaki F., Okawa S., Shigematsu I., Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271–276. doi: 10.1542/peds.54.3.271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.54.3.271</ArticleId><ArticleId IdType="pubmed">4153258</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdoni L., Mazza A., Gervasoni A., Martelli L., Ruggeri M., Ciuffreda M., Bonanomi E., D’Antiga L. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet. 2020;395:1771–1778. doi: 10.1016/S0140-6736(20)31103-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31103-X</ArticleId><ArticleId IdType="pmc">PMC7220177</ArticleId><ArticleId IdType="pubmed">32410760</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker E., Bamford A., Kenny J., Kaforou M., Jones C.E., Shah P., Ramnarayan P., Fraisse A., Miller O., Davies P., et al. Clinical Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2. JAMA. 2020;324:259–269. doi: 10.1001/jama.2020.10369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.10369</ArticleId><ArticleId IdType="pmc">PMC7281356</ArticleId><ArticleId IdType="pubmed">32511692</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Vignesh P., Burgner D. The epidemiology of Kawasaki disease: A global update. Arch. Dis. Child. 2015;100:1084–1088. doi: 10.1136/archdischild-2014-307536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2014-307536</ArticleId><ArticleId IdType="pubmed">26111818</ArticleId></ArticleIdList></Reference><Reference><Citation>Uehara R., Belay E.D. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J. Epidemiol. 2012;22:79–85. doi: 10.2188/jea.JE20110131.</Citation><ArticleIdList><ArticleId IdType="doi">10.2188/jea.JE20110131</ArticleId><ArticleId IdType="pmc">PMC3798585</ArticleId><ArticleId IdType="pubmed">22307434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H., Sugimura T., Akagi T., Sato N., Hashino K., Maeno Y., Kazue T., Eto G., Yamakawa R. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379–1385. doi: 10.1161/01.CIR.94.6.1379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.94.6.1379</ArticleId><ArticleId IdType="pubmed">8822996</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns J.C., Glode M.P. Kawasaki syndrome. Lancet. 2004;364:533–544. doi: 10.1016/S0140-6736(04)16814-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16814-1</ArticleId><ArticleId IdType="pubmed">15302199</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrindle B.W., Rowley A.H., Newburger J.W., Burns J.C., Bolger A.F., Gewitz M., Baker A.L., Jackson M.A., Takahashi M., Shah P.B., et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation. 2017;135:e927–e999. doi: 10.1161/CIR.0000000000000484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000484</ArticleId><ArticleId IdType="pubmed">28356445</ArticleId></ArticleIdList></Reference><Reference><Citation>Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., Shulman S.T., Bolger A.F., Ferrieri P., Baltimore R., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747–2771. doi: 10.1161/01.CIR.0000145143.19711.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000145143.19711.78</ArticleId><ArticleId IdType="pubmed">15505111</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation . Multisystem Inflammatory Syndrome in Children and Adolescents with COVID-19. WHO; Geneva, Switzerland: 2020. Scientific brief.</Citation></Reference><Reference><Citation>Makino N., Nakamura Y., Yashiro M., Sano T., Ae R., Kosami K., Kojo T., Aoyama Y., Kotani K., Yanagawa H. Epidemiological observations of Kawasaki disease in Japan, 2013–2014. Pediatr. Int. 2018;60:581–587. doi: 10.1111/ped.13544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ped.13544</ArticleId><ArticleId IdType="pubmed">29498791</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacke C.E., Breunis W.B., Pereira R.R., Breur J.M., Kuipers I.M., Kuijpers T.W. Five years of Kawasaki disease in the Netherlands: A national surveillance study. Pediatr. Infect. Dis. J. 2014;33:793–797. doi: 10.1097/INF.0000000000000271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000271</ArticleId><ArticleId IdType="pubmed">24463809</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietz S.M., Kuipers I.M., Tacke C.E.A., Koole J.C.D., Hutten B.A., Kuijpers T.W. Giant aneurysms: A gender-specific complication of Kawasaki disease? J. Cardiol. 2017;70:359–365. doi: 10.1016/j.jjcc.2016.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2016.12.014</ArticleId><ArticleId IdType="pubmed">28325522</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda H., Ae R., Koshimizu T.A., Matsumura M., Kosami K., Hayashida K., Makino N., Matsubara Y., Sasahara T., Nakamura Y. Epidemiology and Risk Factors for Giant Coronary Artery Aneurysms Identified after Acute Kawasaki Disease. Pediatr. Cardiol. 2021;42:969–977. doi: 10.1007/s00246-021-02571-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-021-02571-8</ArticleId><ArticleId IdType="pubmed">33682062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T., Miura M., Kobayashi T., Kaneko T., Fukushima N., Suda K., Maeda J., Shimoyama S., Shiono J., Hirono K., et al. Correction to: Analysis of Coronary Arterial Aneurysm Regression in Patients with Kawasaki Disease by Aneurysm Severity: Factors Associated with Regression. J. Am. Heart Assoc. 2023;12:e022417. doi: 10.1161/JAHA.121.022417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.022417</ArticleId><ArticleId IdType="pmc">PMC9973627</ArticleId><ArticleId IdType="pubmed">36718857</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietz S.M., Kuipers I.M., Koole J.C.D., Breur J., Fejzic Z., Frerich S., Dalinghaus M., Roest A.A.W., Hutten B.A., Kuijpers T.W. Regression and Complications of z-score-Based Giant Aneurysms in a Dutch Cohort of Kawasaki Disease Patients. Pediatr. Cardiol. 2017;38:833–839. doi: 10.1007/s00246-017-1590-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-017-1590-0</ArticleId><ArticleId IdType="pmc">PMC5388726</ArticleId><ArticleId IdType="pubmed">28236162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ae R., Abrams J.Y., Maddox R.A., Schonberger L.B., Nakamura Y., Kuwabara M., Makino N., Matsubara Y., Matsubara D., Kosami K., et al. Outcomes in Kawasaki disease patients with coronary artery abnormalities at admission. Am. Heart J. 2020;225:120–128. doi: 10.1016/j.ahj.2020.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2020.04.019</ArticleId><ArticleId IdType="pubmed">32497905</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns J.C., Roberts S.C., Tremoulet A.H., He F., Printz B.F., Ashouri N., Jain S.S., Michalik D.E., Sharma K., Truong D.T., et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): A randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc. Health. 2021;5:852–861. doi: 10.1016/S2352-4642(21)00270-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00270-4</ArticleId><ArticleId IdType="pubmed">34715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ae R., Makino N., Kuwabara M., Matsubara Y., Kosami K., Sasahara T., Nakamura Y. Incidence of Kawasaki Disease before and after the COVID-19 Pandemic in Japan: Results of the 26th Nationwide Survey, 2019 to 2020. JAMA Pediatr. 2022;176:1217–1224. doi: 10.1001/jamapediatrics.2022.3756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2022.3756</ArticleId><ArticleId IdType="pmc">PMC9577881</ArticleId><ArticleId IdType="pubmed">36251290</ArticleId></ArticleIdList></Reference><Reference><Citation>Benezech S., Khoryati L., Cognard J., Netea S.A., Khan T., Moreews M., Saker K., De Guillebon J.-M., Khaldi-Plassart S., Pescarmona R., et al. Pre-Covid-19, SARS-CoV-2-Negative Multisystem Inflammatory Syndrome in Children. N. Engl. J. Med. 2023;389:2105–2107. doi: 10.1056/NEJMc2307574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2307574</ArticleId><ArticleId IdType="pmc">PMC10755832</ArticleId><ArticleId IdType="pubmed">38048195</ArticleId></ArticleIdList></Reference><Reference><Citation>McArdle A.J., Vito O., Patel H., Seaby E.G., Shah P., Wilson C., Broderick C., Nijman R., Tremoulet A.H., Munblit D., et al. Treatment of Multisystem Inflammatory Syndrome in Children. N. Engl. J. Med. 2021;385:11–22. doi: 10.1056/NEJMoa2102968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102968</ArticleId><ArticleId IdType="pmc">PMC8220965</ArticleId><ArticleId IdType="pubmed">34133854</ArticleId></ArticleIdList></Reference><Reference><Citation>Son M.B.F., Murray N., Friedman K., Young C.C., Newhams M.M., Feldstein L.R., Loftis L.L., Tarquinio K.M., Singh A.R., Heidemann S.M., et al. Multisystem Inflammatory Syndrome in Children—Initial Therapy and Outcomes. N. Engl. J. Med. 2021;385:23–34. doi: 10.1056/NEJMoa2102605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102605</ArticleId><ArticleId IdType="pmc">PMC8220972</ArticleId><ArticleId IdType="pubmed">34133855</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara D., Kauffman H.L., Wang Y., Calderon-Anyosa R., Nadaraj S., Elias M.D., White T.J., Torowicz D.L., Yubbu P., Giglia T.M., et al. Echocardiographic Findings in Pediatric Multisystem Inflammatory Syndrome Associated with COVID-19 in the United States. J. Am. Coll. Cardiol. 2020;76:1947–1961. doi: 10.1016/j.jacc.2020.08.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.08.056</ArticleId><ArticleId IdType="pmc">PMC7467656</ArticleId><ArticleId IdType="pubmed">32890666</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattalini M., Della Paolera S., Zunica F., Bracaglia C., Giangreco M., Verdoni L., Meini A., Sottile R., Caorsi R., Zuccotti G., et al. Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: Results from a national, multicenter survey. Pediatr. Rheumatol. Online J. 2021;19:29. doi: 10.1186/s12969-021-00511-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-021-00511-7</ArticleId><ArticleId IdType="pmc">PMC7962084</ArticleId><ArticleId IdType="pubmed">33726806</ArticleId></ArticleIdList></Reference><Reference><Citation>Farooqi K.M., Chan A., Weller R.J., Mi J., Jiang P., Abrahams E., Ferris A., Krishnan U.S., Pasumarti N., Suh S., et al. Longitudinal Outcomes for Multisystem Inflammatory Syndrome in Children. Pediatrics. 2021;148:e2021051155. doi: 10.1542/peds.2021-051155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2021-051155</ArticleId><ArticleId IdType="pubmed">34266903</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteve-Sole A., Anton J., Pino-Ramirez R.M., Sanchez-Manubens J., Fumado V., Fortuny C., Rios-Barnes M., Sanchez-De-Toledo J., Girona-Alarcón M., Mosquera J.M., et al. Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease. J. Clin. Investig. 2021;131 doi: 10.1172/JCI144554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI144554</ArticleId><ArticleId IdType="pmc">PMC7954607</ArticleId><ArticleId IdType="pubmed">33497356</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea S.A., Biesbroek G., van Stijn D., Ijspeert H., van der Made C.I., Jansen M.H., Geissler J., van den Berg J.M., van der Kuip M., Gruppen M.P., et al. Transient anti-cytokine autoantibodies superimpose the hyperinflammatory response in Kawasaki disease and multisystem inflammatory syndrome in children: A comparative cohort study on correlates of disease. eBioMedicine. 2023;95:104736. doi: 10.1016/j.ebiom.2023.104736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104736</ArticleId><ArticleId IdType="pmc">PMC10403726</ArticleId><ArticleId IdType="pubmed">37524002</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreews M., Le Gouge K., Khaldi-Plassart S., Pescarmona R., Mathieu A.L., Malcus C., Djebali S., Bellomo A., Dauwalder O., Perret M., et al. Polyclonal expansion of TCR Vbeta 21.3(+) CD4(+) and CD8(+) T cells is a hallmark of Multisystem Inflammatory Syndrome in Children. Sci. Immunol. 2021;6:eabh1516. doi: 10.1126/sciimmunol.abh1516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abh1516</ArticleId><ArticleId IdType="pmc">PMC8815705</ArticleId><ArticleId IdType="pubmed">34035116</ArticleId></ArticleIdList></Reference><Reference><Citation>Porritt R.A., Binek A., Paschold L., Rivas M.N., McArdle A., Yonker L.M., Alter G., Chandnani H.K., Lopez M., Fasano A., et al. The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. J. Clin. Investig. 2021:131. doi: 10.1172/JCI151520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI151520</ArticleId><ArticleId IdType="pmc">PMC8516454</ArticleId><ArticleId IdType="pubmed">34437303</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm M., Espenhain L., Glenthoj J., Schmidt L.S., Nordly S.B., Hartling U.B., Nygaard U. Risk and Phenotype of Multisystem Inflammatory Syndrome in Vaccinated and Unvaccinated Danish Children before and during the Omicron Wave. JAMA Pediatr. 2022;176:821–823. doi: 10.1001/jamapediatrics.2022.2206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2022.2206</ArticleId><ArticleId IdType="pmc">PMC9178498</ArticleId><ArticleId IdType="pubmed">35675054</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudoin C.A., Pandurangan A.P., Kim S.Y., Hamaia S.W., Huang C.L., Blundell T.L., Vedithi S.C., Jackson A.P. In silico analysis of mutations near S1/S2 cleavage site in SARS-CoV-2 spike protein reveals increased propensity of glycosylation in Omicron strain. J. Med. Virol. 2022;94:4181–4192. doi: 10.1002/jmv.27845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27845</ArticleId><ArticleId IdType="pmc">PMC9348480</ArticleId><ArticleId IdType="pubmed">35575289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>